A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Rifampicin markedly decreases the exposure to oral and intravenous tramadol
Tekijät: Saarikoski T, Saari TI, Hagelberg NM, Neuvonen M, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K
Kustantaja: SPRINGER HEIDELBERG
Julkaisuvuosi: 2013
Journal: European Journal of Clinical Pharmacology
Tietokannassa oleva lehden nimi: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Lehden akronyymi: EUR J CLIN PHARMACOL
Numero sarjassa: 6
Vuosikerta: 69
Numero: 6
Aloitussivu: 1293
Lopetussivu: 1301
Sivujen määrä: 9
ISSN: 0031-6970
DOI: https://doi.org/10.1007/s00228-012-1460-x
Tiivistelmä
Rifampicin markedly decreased the exposure to tramadol and M1 after both oral and intravenous administration. Therefore, rifampicin and other potent enzyme inducers may have a clinically important interaction with tramadol regardless of the route of its administration.
Rifampicin markedly decreased the exposure to tramadol and M1 after both oral and intravenous administration. Therefore, rifampicin and other potent enzyme inducers may have a clinically important interaction with tramadol regardless of the route of its administration.